Elicio Therapeutics, Inc ( (ELTX) ) has released its Q2 earnings. Here is a breakdown of the information Elicio Therapeutics, Inc presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies for cancer patients with limited treatment options. The company recently released its earnings report for the quarter ending June 30, 2025, highlighting its financial performance and strategic developments.
Elicio reported a net loss of $10.6 million for the quarter, an increase from the $7.2 million loss in the same period last year. The company’s operating expenses were primarily driven by research and development costs, which amounted to $7 million, and general administrative expenses totaling $3.1 million. Despite the losses, Elicio raised $22.3 million through various financing activities, including stock offerings and a promissory note, which bolstered its cash position to $22.1 million.
Key financial metrics indicate that Elicio’s total assets increased slightly to $29.5 million from $28.2 million at the end of 2024, while total liabilities decreased significantly from $39.5 million to $27.7 million. The company also reported a change in fair value of warrant liabilities, which resulted in a loss of $0.9 million for the quarter. Additionally, Elicio received grant income of $0.4 million related to its research and development activities.
Looking ahead, Elicio Therapeutics remains focused on advancing its product candidates through clinical trials and securing additional funding to support its operations. The company acknowledges the challenges posed by its current financial condition but is optimistic about future opportunities to collaborate with partners and investors to achieve its strategic goals.